BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 32447795)

  • 21. The science and practice of medication-assisted treatments for opioid dependence.
    Pecoraro A; Ma M; Woody GE
    Subst Use Misuse; 2012; 47(8-9):1026-40. PubMed ID: 22676570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characteristics and current clinical practices of opioid treatment programs in the United States.
    Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
    Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Opioids: The Forgotten Epidemic?
    Price S
    Tex Med; 2020 Oct; 116(10):32-35. PubMed ID: 33126270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
    Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
    J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
    [No Abstract]   [Full Text] [Related]  

  • 25. Managing emergency department patients with opioid use disorder.
    Hazekamp CS; Sacco D
    Emerg Med Pract; 2024 Jun; 26(6):1-24. PubMed ID: 38768011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The case for a medication first approach to the treatment of opioid use disorder.
    Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T
    Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515
    [No Abstract]   [Full Text] [Related]  

  • 27. Opioid use disorder and the COVID 19 pandemic: A call to sustain regulatory easements and further expand access to treatment.
    Green TC; Bratberg J; Finnell DS
    Subst Abus; 2020; 41(2):147-149. PubMed ID: 32314951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early Effects of COVID-19 on Programs Providing Medications for Opioid Use Disorder in Jails and Prisons.
    Bandara S; Kennedy-Hendricks A; Merritt S; Barry CL; Saloner B
    J Addict Med; 2020; 14(5):e257-e260. PubMed ID: 32868681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study.
    Sufrin C; Sutherland L; Beal L; Terplan M; Latkin C; Clarke JG
    Addiction; 2020 Nov; 115(11):2057-2065. PubMed ID: 32141128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of Opioid Overdose.
    Babu KM; Brent J; Juurlink DN
    N Engl J Med; 2019 Jun; 380(23):2246-2255. PubMed ID: 31167053
    [No Abstract]   [Full Text] [Related]  

  • 31. Patient perceptions of treatment with medication treatment for opioid use disorder (MOUD) in the Vermont hub-and-spoke system.
    Rawson RA; Rieckmann T; Cousins S; McCann M; Pearce R
    Prev Med; 2019 Nov; 128():105785. PubMed ID: 31362002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial.
    Hser YI; Evans E; Huang D; Weiss R; Saxon A; Carroll KM; Woody G; Liu D; Wakim P; Matthews AG; Hatch-Maillette M; Jelstrom E; Wiest K; McLaughlin P; Ling W
    Addiction; 2016 Apr; 111(4):695-705. PubMed ID: 26599131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.
    Cottrill CB; Matson SC
    Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacological treatment of opioid use disorder in pregnancy.
    Rodriguez CE; Klie KA
    Semin Perinatol; 2019 Apr; 43(3):141-148. PubMed ID: 30755340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unprecedented need and recommendations for harnessing data to guide future policy and practice for opioid use disorder treatment following COVID-19.
    Livingston NA; Ameral V; Banducci AN; Weisberg RB
    J Subst Abuse Treat; 2021 Mar; 122():108222. PubMed ID: 33303255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Caring for patients with opioid use disorder in the hospital.
    Donroe JH; Holt SR; Tetrault JM
    CMAJ; 2016 Dec; 188(17-18):1232-1239. PubMed ID: 27647616
    [No Abstract]   [Full Text] [Related]  

  • 37. Update on Barriers to Pharmacotherapy for Opioid Use Disorders.
    Sharma A; Kelly SM; Mitchell SG; Gryczynski J; O'Grady KE; Schwartz RP
    Curr Psychiatry Rep; 2017 Jun; 19(6):35. PubMed ID: 28526967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Buprenorphine for Persons on Waiting Lists for Treatment for Opioid Dependence.
    Yan K
    N Engl J Med; 2017 Mar; 376(10):1000. PubMed ID: 28276662
    [No Abstract]   [Full Text] [Related]  

  • 39. Buprenorphine for Persons on Waiting Lists for Treatment for Opioid Dependence.
    Sigmon SC; Schwartz RP; Higgins ST
    N Engl J Med; 2017 Mar; 376(10):1000-1001. PubMed ID: 28273017
    [No Abstract]   [Full Text] [Related]  

  • 40. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
    Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
    Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.